vTv Therapeutics (NASDAQ:VTVT) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVTGet Rating) in a research report issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

A number of other brokerages also recently weighed in on VTVT. Cantor Fitzgerald started coverage on shares of vTv Therapeutics in a research note on Friday, February 18th. They set an “overweight” rating and a $5.00 target price for the company. Zacks Investment Research upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a report on Tuesday, April 5th.

VTVT opened at $0.77 on Wednesday. vTv Therapeutics has a 52 week low of $0.49 and a 52 week high of $2.88. The firm has a market capitalization of $68.88 million, a PE ratio of -3.48 and a beta of -1.59. The company has a fifty day moving average price of $0.70 and a two-hundred day moving average price of $0.98.

vTv Therapeutics (NASDAQ:VTVTGet Rating) last issued its earnings results on Tuesday, March 29th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.08). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $1.00 million. Equities analysts forecast that vTv Therapeutics will post -0.2 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley grew its stake in vTv Therapeutics by 1,575.3% during the second quarter. Morgan Stanley now owns 36,756 shares of the biotechnology company’s stock valued at $83,000 after acquiring an additional 34,562 shares in the last quarter. Rafferty Asset Management LLC purchased a new position in vTv Therapeutics in the 3rd quarter worth approximately $83,000. Geode Capital Management LLC grew its stake in vTv Therapeutics by 77.2% in the 3rd quarter. Geode Capital Management LLC now owns 347,635 shares of the biotechnology company’s stock worth $531,000 after buying an additional 151,435 shares in the last quarter. GSA Capital Partners LLP purchased a new position in vTv Therapeutics in the 3rd quarter worth approximately $177,000. Finally, Two Sigma Securities LLC purchased a new stake in shares of vTv Therapeutics in the 3rd quarter valued at $26,000. 72.12% of the stock is currently owned by institutional investors.

vTv Therapeutics Company Profile (Get Rating)

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.

Featured Stories

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.